Trulance is NOT Contraindicated in Gastric Bypass, Atrial Fibrillation, or Coronary Artery Disease
Trulance (plecanatide) has only two absolute contraindications according to FDA labeling: patients under 6 years of age (due to dehydration risk) and patients with known or suspected mechanical gastrointestinal obstruction 1. None of the conditions you mentioned—gastric bypass surgery, atrial fibrillation, or coronary artery disease—appear in the contraindications list.
What the FDA Label Actually Says
The official prescribing information explicitly lists only these contraindications 1:
- Patients less than 6 years of age (risk of serious dehydration)
- Known or suspected mechanical GI obstruction
That's it. No mention of cardiac conditions, prior bariatric surgery, or cardiovascular disease.
Why This Matters Clinically
Plecanatide is a guanylate cyclase-C agonist that works locally in the GI tract by increasing intestinal fluid secretion 2. It is:
- Minimally absorbed systemically (acts luminally in the gut)
- No significant drug-drug interactions with cardiac medications
- No cardiovascular effects documented in clinical trials
The 2023 AGA-ACG guidelines strongly recommend plecanatide for chronic idiopathic constipation in adults who don't respond to over-the-counter agents, with moderate certainty of evidence 2. These guidelines make no restrictions based on cardiac comorbidities or prior bariatric surgery.
Safety Profile Relevant to Your Question
In Older Adults (Often with CAD/AFib)
Studies specifically evaluated patients ≥65 years—a population with high prevalence of coronary disease and atrial fibrillation. Plecanatide showed similar efficacy and safety in this age group compared to younger patients, with no new safety signals 3.
Primary Adverse Event: Diarrhea
The main concern with plecanatide is diarrhea (4.3% vs 1.0% placebo), leading to discontinuation in only 1.2% of patients 4. This is a GI side effect, not a cardiovascular one.
No Cardiac Safety Signals
Across multiple phase 3 trials involving over 4,800 patients, there were no cardiovascular adverse events attributed to plecanatide 2, 4.
Clinical Caveats
Watch for dehydration risk in patients taking diuretics for heart failure or hypertension—the diarrhea side effect could theoretically worsen volume depletion, though this wasn't reported as a significant issue in trials. This is a monitoring consideration, not a contraindication.
Gastric bypass patients may have altered GI anatomy, but plecanatide acts in the small intestine and colon (downstream from the gastric pouch), so the mechanism of action remains intact. No evidence suggests reduced efficacy or increased risk post-bariatric surgery.
Bottom Line Algorithm
Can you prescribe Trulance?
- Is the patient <6 years old? → NO (absolute contraindication)
- Does the patient have mechanical bowel obstruction? → NO (absolute contraindication)
- Does the patient have gastric bypass, AFib, or CAD? → YES, you can prescribe it
Monitoring in cardiac patients:
- Ensure adequate hydration, especially if on diuretics
- Standard dose: 3 mg once daily
- Counsel about diarrhea risk (occurs early if it happens)
- No need for cardiac monitoring or dose adjustment
The evidence is clear: cardiac disease and prior bariatric surgery are not contraindications to Trulance 1.